Zosurabalpin: an antibiotic with a new mechanism of action against carbapenem-resistant Acinetobacter baumannii
- PMID: 40519345
- PMCID: PMC12160509
- DOI: 10.53854/liim-3302-3
Zosurabalpin: an antibiotic with a new mechanism of action against carbapenem-resistant Acinetobacter baumannii
Abstract
Background: Carbapenem-resistant Acinetobacter baumannii (CRAB) poses a critical global health threat, particularly among hospitalized and critically ill patients, due to its association with severe, difficult-to-treat infections. Its high resistance stems from genomic plasticity, biofilm formation, and environmental persistence, leading to limited treatment options and high mortality. Existing treatments often rely on sulbactam-based combinations, yet resistance continues to rise and new agents remain limited.
Aims: This review aims to highlight the therapeutic potential of zosurabalpin, a first-in-class lipopolysaccharide (LPS) transport inhibitor with selective activity against A. baumannii, by summarizing preclinical and early clinical data on its efficacy, mechanism of action, pharmacokinetics, and safety.
Sources: Peer-reviewed publications from PubMed and Scopus, clinical data from ClinicalTrials.gov, and relevant conference materials ECCMID and IDWeek.
Content: Zosurabalpin inhibits the LptB-FGC complex, blocking LPS transport and causing lethal intracellular accumulation. Preclinical data demonstrate potent in vitro and in vivo activity against CRAB, with high selectivity and favorable pharmacokinetics. Phase 1 studies report good tolerability and a promising safety profile.Its novel mechanism makes zosurabalpin a strong candidate for treating CRAB.
Implications: With rising resistance and limited effective treatments, zosurabalpin offers a new, targeted therapeutic approach. Continued clinical development could help close a critical gap in the management of multidrug-resistant Acinetobacter baumannii.
Keywords: Carbapenem-resistant Acinetobacter baumannii (CRAB); LPS transport inhibitors; lipopolysaccharide (LPS) transport system; zosurabalpin.
Conflict of interest statement
Conflicts of interest: The authors have no conflicts of interest to report.
Figures
Similar articles
-
In silico analysis of zosurabalpin-LptB2FG binding in Acinetobacter spp., Klebsiella pneumoniae, and Shigella flexneri: mechanisms underlying its differential efficacy.In Silico Pharmacol. 2025 Apr 16;13(2):62. doi: 10.1007/s40203-025-00343-3. eCollection 2025. In Silico Pharmacol. 2025. PMID: 40255254
-
Unraveling sulbactam-durlobactam: insights into its role in combating infections caused by Acinetobacter baumannii.Expert Rev Anti Infect Ther. 2025 Jan;23(1):67-78. doi: 10.1080/14787210.2024.2440018. Epub 2024 Dec 19. Expert Rev Anti Infect Ther. 2025. PMID: 39644103 Review.
-
Optimizing Treatment for Carbapenem-Resistant Acinetobacter baumannii Complex Infections: A Review of Current Evidence.Infect Chemother. 2024 Jun;56(2):171-187. doi: 10.3947/ic.2024.0055. Infect Chemother. 2024. PMID: 38960737 Free PMC article. Review.
-
A novel antibiotic class targeting the lipopolysaccharide transporter.Nature. 2024 Jan;625(7995):566-571. doi: 10.1038/s41586-023-06873-0. Epub 2024 Jan 3. Nature. 2024. PMID: 38172634 Free PMC article.
-
Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii.Antibiotics (Basel). 2023 Dec 14;12(12):1729. doi: 10.3390/antibiotics12121729. Antibiotics (Basel). 2023. PMID: 38136764 Free PMC article. Review.
References
-
- O’Donnell JN, Putra V, Lodise TP. Treatment of patients with serious infections due to carbapenem-resistant Acinetobacter baumannii: how viable are the current options? Pharmacotherapy. 2021;41(9):762–780. - PubMed
-
- Butler DA, Biagi M, Tan X, et al. Multidrug resistant Acinetobacter baumannii: resistance by any other name would still be hard to treat. Curr Infect Dis Rep. 2019;21(12):46. - PubMed
-
- Shan W, Kan J, Cai X, et al. Insights into mucoid Acinetobacter baumannii: a review of microbiological characteristics, virulence, and pathogenic mechanisms in a threatening nosocomial pathogen. Microbiol Res. 2022;261:127057. - PubMed
-
- Cruz-López F, Martínez-Meléndez A, Villareal-Treviño L, et al. Contamination of healthcare environment by carbapenem-resistant Acinetobacter baumannii. Am J Med Sc. 2022;364(6):685–694. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous